Article
MEK targeting in N-RAS mutated metastatic melanoma.
Molecular cancer - 4 Mar 2014
Thumar Jaykumar, Shahbazian David, Aziz Saadia A, Jilaveanu Lucia B, Kluger Harriet M
Abstract excerpt
BACKGROUND: Gain of function mutations in B-RAF and N-RAS occur frequently in melanoma, leading to mitogen activating protein kinase (MAPK) pathway activation, and this pathway is the target of drugs in development. Our purpose was to study clinical characteristics of patients with mutations in this pathway and to determine activity of inhibitors of B-RAF and MEK in short term cultures grown from tumors of some...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.